Our aim was to investigate the effects of probiotics on glucose metabolism in patients with type 2 diabetes mellitus using a meta-analysis of randomized, controlled trials. Online databases Embase, Web of Science, and PubMed were searched until August 2014 to identify eligible articles. Finally, 7 trials were included. Probiotic consumption significantly changed fasting plasma glucose (FPG) by -15.92mg/dL (95% confidence interval [CI], -29.75 to -2.09) and glycosylated hemoglobin (HbA1c) by -0.54% (95% CI, -0.82 to -0.25) compared with control groups. Subgroup analysis was conducted to trials with non-yogurts control. Meta-analysis of trials with multiple species of probiotics found a significant reduction in FPG (weighted mean difference [WMD]: -35.41mg/dL, 95% CI: -51.98 to -18.89). The duration of intervention for ≥8 weeks resulted in a significant reduction in FPG (WMD: -20.34mg/dL, 95% CI: -35.92 to -4.76). Subgroup analysis of trials with species of probiotics did not result in a significant meta-analysis effect. Furthermore, the duration of intervention <8 weeks did not result in a significant reduction in FPG. The results also showed that probiotic therapy significantly decreased homeostasis model assessment of insulin resistance (HOMA-IR) and insulin concentration (WMD: -1.08, 95% CI: -1.88 to -0.28; and WMD: -1.35mIU/L, 95% CI: -2.38 to -0.31, respectively). The present meta-analysis suggests that consuming probiotics may improve glucose metabolism by a modest degree, with a potentially greater effect when the duration of intervention is ≥8 weeks, or multiple species of probiotics are consumed.
The present study reported on an intrinsic property of gold nanoparticles (Au‑NPs), namely their ability to inhibit the proliferation and invasion of thyroid carcinoma cells. Au‑NPs of various sizes (5‑60 nm) were synthesized and their uptake into the SW579 human thyroid carcinoma cell line was verified using transmission electron microscopy (TEM). The viability, apoptosis, cell cycle distribution and invasive capacity of SW579 cells were assessed following treatment with Au‑NPs using a Cell Counting Kit‑8 assay, flow cytometric analysis and a Transwell as well as a fluorometric invasion assay. TEM demonstrated that all sizes of Au‑NPs could be taken up by the SW579 cells. The results showed that small‑sized Au‑NPs (5 and 10 nm) significantly suppressed the proliferation and invasion of SW579 cells and induced apoptosis as well as cell cycle arrest in G0/G1 phase, while larger‑sized gold nanoparticles (20‑60 nm) did not exert these effects, therefore suggesting that the effects of Au‑NPs on SW579 cells were highly associated with their particle size. The reduction of the invasive capacity of SW579 cells following treatment with Au‑NPs may be attributed to decreases in the expression of matrix metalloproteinase‑2 and ‑9, which were observed using western blot and reverse‑transcription quantitative polymerase chain reaction analyses. The present study was the first to demonstrate that small‑sized Au‑NPs inhibit the proliferation and invasion of thyroid carcinoma cells, which may contribute to the advancement of biomedical applications of Au‑NPs.
1 November 2024 in Risk Management and Healthcare Policy
Objective: To determine the prevalence of Cardiovascular-Kidney-Metabolic (CKM) Syndrome and identify risk factors, including occupational factors, lifestyle factors and clinical measurements, and female-specific risk enhancers among healthcare workers in China. Methods: A cross-sectional study was conducted among healthcare workers at Taizhou People’s Hospital between April and May 2024. We collected data through surveys and laboratory results. Univariate and multivariate logistic regression analyses were performed to identify predictors of CKM syndrome and female-specific risk enhancers. Results: A total of 1110 participants were recruited (197 male; 913 female; mean age 34.8± 7.9). Almost 90% of male healthcare workers and 60% of female healthcare workers met the criteria for CKM syndrome (stage 1 or higher). Additionally, most male CKM syndrome patients were in stages 2– 3 (53.81%), while most female CKM syndrome patients were in stage 1 (35.82%). Multivariate logistic regression analysis revealed that, compared to those with over 20 years of work duration, a work duration of less than 10 years was a protective factor for CKM Syndrome. Additionally, more than 8 hours of sedentary time was identified as a risk factor compared to less than 2 hours (OR = 1.376, 95% CI 1.027– 1.844, P < 0.05). Receiver operating characteristic analysis showed that body mass index (BMI) was superior to fasting plasma glucose, glycated hemoglobin, triglycerides, and the triglyceride glucose product index in predicting CKM Syndrome, with area under the curve values of 0.884 vs 0.638, 0.708, 0.745, and 0.761, respectively (P < 0.05 for all). BMI was identified as an independent risk factor for female-specific risk enhancers. Conclusion: CKM syndrome is prevalent among healthcare workers in Chinese tertiary hospitals, with males generally presenting at more advanced stages than females. BMI is a key predictor of CKM syndrome and female-specific risk enhancers.
Background: The relationship between a low TyG index and mortality risk in Acute Decompensated Heart Failure (ADHF) also remains unclear. This study aimed to investigate the association between a low TyG index and 1-year mortality in ADHF patients without diabetes. Methods: A total of 652 hospitalized patients with ADHF without diabetes from January, 2020 to May, 2023 were included in this retrospective study. The primary outcomes were all-cause mortality and cardiovascular mortality within one year. The association between the TyG index and both all-cause and cardiovascular mortality was investigated using restricted cubic splines and multivariate Cox proportional hazards models. Results: The study enrolled a total of 652 patients with acute decompensated heart failure (ADHF) who were free from diabetes (70.6% male). Within one year, there were 72 deaths from all causes and 40 deaths from cardiovascular disease. In multivariate Cox proportional hazards models, a significant negative relationship was observed between the TyG index and both all-cause mortality (hazard ratio [HR] = 0.371, 95% confidence interval [CI] 0.201– 0.685) and cardiovascular mortality (HR = 0.336, 95% CI 0.151– 0.744). The restricted cubic spline analysis illustrated a decrease in the risk of all-cause and cardiovascular mortality as the TyG index increased. Hypertension, BMI, age, atrial fibrillation significantly interacted with the TyG index in relation to all-cause mortality, while hypertension specifically interacted with the TyG index regarding cardiovascular mortality. Conclusion: In patients diagnosed with ADHF without diabetes, a lower TyG index is strongly related to a higher risk of 1-year all-cause and cardiovascular mortality. Therefore, it is important to pay close attention to low TyG index levels and implement appropriate measures in clinical practice.
23 December 2021 in Journal of International Medical Research
Aim: To assess the effects of incretin-based therapies on β-cell function in patients with type 1 diabetes mellitus (T1DM). Methods: We searched the PubMed, Cochrane Library, Embase, and Web of Knowledge databases for eligible randomized clinical trials published up to July 2021. The inclusion criteria were patients with T1DM or latent autoimmune diabetes in adults, patients treated with dipeptidyl peptidase-4 inhibitors or glucagon like peptide-1 receptor agonists, and outcomes included one of the following: fasting plasma glucose, fasting C-peptide, postprandial C-peptide, C-peptide area under the curve (AUC), homeostasis model assessment for β cell function, and insulin resistance. The effects were analyzed using a random effect model with STATA 11.0. Results: Eight trials including 427 participants were included in the final analysis. A pooled analysis found no significant difference in fasting plasma glucose, fasting C-peptide, postprandial C-peptide, or C-peptide AUC between patients treated with incretin-based therapies and placebo. The two trials that reported changes in 2-hour postprandial C-peptide and two of the four trials that reported changes in C-peptide AUC reported increases after incretin-based therapies. Conclusion: This meta-analysis showed that incretin-based therapies did not preserve β-cell function in patients with T1DM.